Steroids and 5-aminosalicylic acids in moderate ulcerative colitis: addressing the dilemma

被引:17
作者
Probert, Chris [1 ]
机构
[1] Univ Liverpool, Inst Translat Med, Dept Gastroenterol, Henry Wellcome Lab, Liverpool L69 3GE, Merseyside, England
关键词
5-aminosalicylic acid; inflammatory bowel disease; mesalazine; steroid avoidance; steroids; ulcerative colitis; INFLAMMATORY-BOWEL-DISEASE; EVIDENCE-BASED CONSENSUS; RELEASE ORAL MESALAMINE; DOUBLE-BLIND; MMX MESALAMINE; MESALAZINE; MANAGEMENT; INDUCTION; REMISSION; THERAPY;
D O I
10.1177/1756283X12461395
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Steroids have been a mainstay of ulcerative colitis (UC) therapy for many years, based on a thoroughly established efficacy profile for the induction of remission. However, in light of the considerable side effects and negative perceptions they carry, it is important to ensure such treatments are used as effectively as possible. For severe UC, the need for steroids is rarely questioned, and rightly so; it is for moderate UC that the role of steroids should be considered. Both patients and clinicians place a high importance on rapid, effective resolution of symptoms, yet at the same time wish to avoid unnecessary side effects. Through consideration of the available evidence, it becomes clear that both steroids and high-dose 5-aminosalicylic acid (5-ASA) are supported by robust trials demonstrating their efficacy. Indeed, both therapies have been shown to give rise to resolution of symptoms after 2 weeks in many patients. However, a paucity of head-to-head comparisons makes conclusive interpretation challenging. This paper therefore presents a practical approach, which builds on the available evidence and is developed from informed discussions with patients. This approach involves initiating therapy with high-dose 5-ASA, followed by a review of symptom improvements after 2-3 weeks. Steroids can then be introduced, when needed, with minimal delay. In this way, symptoms can be resolved rapidly, yet many patients may avoid unpleasant side effects.
引用
收藏
页码:33 / 38
页数:6
相关论文
共 20 条
[1]   Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study [J].
Campieri, M ;
Adamo, S ;
Valpiani, D ;
D'Arienzo, A ;
D'Albasio, G ;
Pitzalis, M ;
Cesari, P ;
Casetti, T ;
Castiglione, GN ;
Rizzello, F ;
Manguso, F ;
Varoli, G ;
Gionchetti, P .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (12) :1471-1480
[2]   Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis [J].
Ford, Alexander C. ;
Bernstein, Charles N. ;
Khan, Khurram J. ;
Abreu, Maria T. ;
Marshall, John K. ;
Talley, Nicholas J. ;
Moayyedi, Paul .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (04) :590-599
[3]   Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis [J].
Frieri, G ;
Pimpo, M ;
Galletti, B ;
Palumbo, G ;
Corrao, G ;
Latella, G ;
Chiaramonte, M ;
Caprilli, R .
DIGESTIVE AND LIVER DISEASE, 2005, 37 (02) :92-96
[4]   Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial [J].
Hanauer, SB ;
Sandborn, WJ ;
Kornbluth, A ;
Katz, S ;
Safdi, M ;
Woogen, S ;
Regalli, G ;
Yeh, C ;
Smith-Hall, N ;
Ajayi, F .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (11) :2478-2485
[5]   Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared with 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial [J].
Hanauer, Stephen B. ;
Sandborn, William J. ;
Dallaire, Christian ;
Archambault, Andre ;
Yacyshyn, Bruce ;
Yeh, Chyon ;
Smith-Hall, Nancy .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 21 (12) :827-834
[6]   Once-daily, high-concentration MMX mesalamine in active ulcerative colitis [J].
Kamm, Michael A. ;
Sandborn, William J. ;
Gassull, Miguel ;
Schreiber, Stefan ;
Jackowski, Lechoslaw ;
Butler, Todd ;
Lyne, Andrew ;
Stephenson, David ;
Palmen, Mary ;
Joseph, Raymond E. .
GASTROENTEROLOGY, 2007, 132 (01) :66-75
[7]   Review article: understanding adherence to medication in ulcerative colitis - innovative thinking and evolving concepts [J].
Kane, S. V. ;
Robinson, A. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 32 (09) :1051-1058
[8]   AN ASSESSMENT OF PREDNISONE, SALAZOPYRIN, AND TOPICAL HYDROCORTISONE HEMISUCCINATE USED AS OUT-PATIENT TREATMENT FOR ULCERATIVE COLITIS [J].
LENNARDJONES, JE ;
LONGMORE, AJ ;
NEWELL, AC ;
WILSON, CWE ;
JONES, FA .
GUT, 1960, 1 (03) :217-222
[9]   Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis [J].
Lichtenstein, Gary R. ;
Kamm, Michael A. ;
Boddu, Prabhakar ;
Gubergrits, Natalya ;
Lyne, Andrew ;
Butler, Todd ;
Lees, Kirstin ;
Joseph, Raymond E. ;
Sandborn, William J. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2007, 5 (01) :95-102
[10]   A practical perspective on ulcerative colitis: Patients' needs from aminosalicylate therapies [J].
Loftus, Edward V., Jr. .
INFLAMMATORY BOWEL DISEASES, 2006, 12 (12) :1107-1113